Treating Toenail Fungus With Vinega... Dec 3, 2008
Onychomycosis, commonly known as nail fungus, is the most common disease affecting human nails. While cases of fingernail infection do exist, nail fungus most commonly affects the toenails. (Suite101.com)
New topical approach to treating nail fungus circumvents problems with current therapy Oct 29, 2008
The data represent a unique approach to treating nail fungus (onychomycosis), which resists topical therapies because they cannot penetrate the nail and access the site of infection ... "The average great toenail measures 22 millimeters across, so we are able to deliver NB-002 across the entire span of an infected human large toenail, a huge advance in the treatment of onychomycosis," Ciotti said ... Newer, more effective therapies for nail fungus are important because onychomycosis remains a... (EurekAlert!)
New intranasal influenza vaccine triggers robust immunity with significantly less antigen Oct 29, 2008
The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne and mucosal vaccines for seasonal and pandemic influenza, hepatitis B, RSV and pneumococcal. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich. (EurekAlert!)
Arpida Announces FDA Acceptance of the Iclaprim New Drug Application May 16, 2008
Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis. Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages. (PR Newswire)
Barrier Therapeutics Announces Positive Results in Reducing Itch Symptoms With Novel Oral Antihistamine Agent Hivenyl Apr 9, 2008
Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. (Primezone Releases)
Barrier Therapeutics Announces Positive Results of Dose Escalation Clinical Safety Study With Pramiconazole Nov 27, 2007
The total of 6 grams administered over five days is 30 times higher than the single weekly dose of 200 mg of pramiconazole that is being used in a Phase 2a study in toenail onychomycosis (nail fungus) currently underway in Europe ... When we consider these data along with previously reported clinical efficacy results in onychomycosis and other fungal infections, we continue to believe there is a strong clinical rationale for advancing this product candidate to the next stage of development ...... (Primezone Releases)
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim Nov 21, 2007
Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis. Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages. (PR Newswire)
Macrochem acquires option to license pexiganan Jul 11, 2007
This trial was specifically designed, with the assistance of well-known onychomycosis experts, to address three important objectives: to assess early signs of efficacy, to maintain robust clinical endpoints in the full study, and, if successful, to facilitate advancement to Phase 3 as soon as possible. . (EurekAlert! -- Business News)
Schering-Plough, Anacor ink deal Feb 5, 2007
-based Anacor said the agreement with New Jersey-based Schering-Plough covers development and commercialization of the drug, which is currently in phase 2 clinical trials for onychomycosis, a fungal infection of the nail and nail bed ... Schering-Plough will assume all costs for the drug's development for onychomycosis and other indications, and Anacor retains an option to co-promote the drug in the U.S. to dermatologists. (Memphis Business Journal, TN)
